Zevra Therapeutics, Inc. Paid-in-Kind Interest
Zevra Therapeutics, Inc. (ZVRA) reported Paid-in-Kind Interest of $2.65 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-03-09
- Zevra Therapeutics, Inc. paid-in-kind interest for the quarter ending 2025-12-31 was $612.00K, a 2.00% increase year-over-year.
- Zevra Therapeutics, Inc. paid-in-kind interest for the quarter ending 2025-09-30 was $685.00K, a 12.07% decline year-over-year.
- Zevra Therapeutics, Inc. paid-in-kind interest for the quarter ending 2025-06-30 was $689.00K, a 46.28% increase year-over-year.
- Zevra Therapeutics, Inc. paid-in-kind interest for the quarter ending 2025-03-31 was $663.00K, a 177.41% increase year-over-year.
- Zevra Therapeutics, Inc. paid-in-kind interest for fiscal 2025 was $2.65M, a 26.81% increase from fiscal 2024.
- Zevra Therapeutics, Inc. paid-in-kind interest for fiscal 2024 was $2.09M.
- Zevra Therapeutics, Inc. paid-in-kind interest for fiscal 2023 was $0.00.
- Zevra Therapeutics, Inc. paid-in-kind interest for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2025-12-31 | $612.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.30M derived: sum of 2 quarters · filed 2026-03-09 | $1.99M derived: sum of 3 quarters · filed 2026-03-09 | $2.65M 10-K · filed 2026-03-09 |
| 2025-09-30 | $685.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.37M derived: sum of 2 quarters · filed 2025-11-05 | $2.04M 10-Q · filed 2025-11-05 | $2.64M derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-06-30 | $689.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.35M 10-Q · filed 2025-08-12 | $1.95M derived: sum of 3 quarters · filed 2026-03-09 | $2.73M derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-03-31 | $663.00K 10-Q · filed 2025-05-13 | $1.26M derived: sum of 2 quarters · filed 2026-03-09 | $2.04M derived: sum of 3 quarters · filed 2026-03-09 | $2.51M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.38M derived: sum of 2 quarters · filed 2026-03-09 | $1.85M derived: sum of 3 quarters · filed 2026-03-09 | $2.09M 10-K · filed 2026-03-09 |
| 2024-09-30 | $779.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.25M derived: sum of 2 quarters · filed 2025-11-05 | $1.49M 10-Q · filed 2025-11-05 | $1.49M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $471.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $710.00K 10-Q · filed 2025-08-12 | $710.00K derived: sum of 3 quarters · filed 2025-08-12 | $710.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $239.00K 10-Q · filed 2025-05-13 | $239.00K derived: sum of 2 quarters · filed 2025-05-13 | $239.00K derived: sum of 3 quarters · filed 2025-05-13 | $239.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $0.00 derived: sum of 2 quarters · filed 2025-03-12 | $0.00 derived: sum of 3 quarters · filed 2025-03-12 | $0.00 10-K · filed 2025-03-12 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2024-08-14 | $0.00 derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-05-09 | $0.00 derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $0.00 10-K · filed 2023-03-07 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-12 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $8.00K 10-K · filed 2023-03-07 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $8.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $8.00K 10-Q · filed 2022-08-12 | |||
| 2020-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $2.31M derived: sum of 2 quarters · filed 2022-03-31 | $3.50M derived: sum of 3 quarters · filed 2022-03-31 | $4.74M 10-K · filed 2022-03-31 |
| 2020-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.34M derived: sum of 2 quarters · filed 2021-11-10 | $3.58M 10-Q · filed 2021-11-10 | $4.01M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $2.43M 10-Q · filed 2021-08-13 | $2.86M derived: sum of 3 quarters · filed 2021-08-13 | $1.93M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $1.24M 10-Q · filed 2021-05-14 | $1.67M derived: sum of 2 quarters · filed 2021-05-14 | $742.00K derived: sum of 3 quarters · filed 2021-05-14 | $1.80M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $429.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$502.00K derived: sum of 2 quarters · filed 2021-03-12 | $554.00K derived: sum of 3 quarters · filed 2021-03-12 | $1.42M 10-K · filed 2021-03-12 |
| 2019-09-30 | -$931.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $125.00K derived: sum of 2 quarters · filed 2020-10-30 | $988.00K 10-Q · filed 2020-10-30 | $1.95M derived: sum of 4 quarters · filed 2020-10-30 |
| 2019-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $1.92M 10-Q · filed 2020-08-12 | $2.88M derived: sum of 3 quarters · filed 2020-08-12 | |
| 2019-03-31 | $863.00K 10-Q · filed 2020-05-13 | $1.83M derived: sum of 2 quarters · filed 2020-05-13 | ||
| 2018-12-31 | $966.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $2.09M 10-K · filed 2020-02-28 | ||
| 2018-09-30 | $1.12M 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |